- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05425654
RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
Rituximab, Methotrexate, Procarbazine, Vincristine, Lenalidomide (RL-MPV) Followed by BBC (BCNU, Busulfan, Cyclophosphamide) High-dose Chemotherapy With Auto-HCT and Maintenance Therapy With Nivolumab in Newly Diagnosed Primary CNS Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Eugene Zvonkov, Phd, MD
- Phone Number: +7 (495) 612-13-31
- Email: dr.zvonkov@mail.ru
Study Contact Backup
- Name: Daria Koroleva, Phd
- Phone Number: +7 (495) 612-13-31
- Email: koroleva_12-12@mail.ru
Study Locations
-
-
-
Moscow, Russian Federation, 125167
- Recruiting
- Nathional Medical Research Center for Hematology
-
Contact:
- Eugene Zvonkov, PhD/MD
- Phone Number: +7 (495) 612-13-31
- Email: dr.zvonkov@mail.ru
-
Contact:
- Daria Koroleva, PhD
- Phone Number: + 7 (964) 717-53-12
- Email: koroleva_12-12@mail.ru
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All patients must have non-Hodgkin's lymphoma involving the brain, as demonstrated by CT or MRI and histologic confirmation by one of the following: A positive CSF cytology for lymphoma or a monoclonal lymphocyte population as defined by cell surface markers.
A biopsy of the vitreous or uvea demonstrating non-Hodgkin's lymphoma. Brain biopsy.
Patients must be HIV-1 negative. Patient must have left ventricular ejection fraction ≥ 50%. Patients must have no evidence of systemic lymphoma. This must be demonstrated by a CT scan of the chest, abdomen and pelvis prior to registration.
Patients must have adequate bone marrow function (defined as peripheral leucocyte count >3000 cells/mm3 and platelet count > 100,000 cells/mm3), liver function (bilirubin < 2.0 mg/%), and adequate renal function (serum creatinine < 1.5 mg/dl or creatinine clearance > 50cc/min/1.73M2).
Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.
Patients must be between 18 and 70years-old. Patients must sign an informed consent.
Exclusion Criteria:
Prior cranial irradiation Other active primary malignancy. Pre-existing immunodeficiency such as renal transplant recipient. Prior treatment with chemotherapy for CNS lymphoma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RL-MPV + BBC/auto-HCT+ nivolumab
Rituximab, methotrexate (MTX), procarbazine, vincristine and lenalidomide (RL-MPV).
The peripheral blood stem cell (PBSC) harvest procedure will be performed after 2nd cycle of RL-MPV.
High dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide.
3 months after auto-HSCT, maintenance therapy with nivolumab 3 mg/kg is started for 6 months every 2 weeks
|
The initial treatment will consist of cycles of 14 days.
Each cycle will start with rituximab, which will be given by vein on day 1.
On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes.
Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle.
During each cycle, you will be in the hospital.
After the second cycle of chemotherapy, PBPCs will be collected.
You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions.
Busulfan, carmustine and cyclophosphamide will be given to you for 5 days.
After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein.
You will be in the hospital for at least 3 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
frequency of adverse events
Time Frame: Time Frame: 1-year event-free survival and acute treatment-related toxicity.]
|
to evaluate the frequency of adverse events (safety and efficacy) of the use of RL-MPV followed by high-dose chemotherapy using carmustine, cyclophosphamide and busulfan with stem cell rescue in patients with newly diagnosed PCSNL.
|
Time Frame: 1-year event-free survival and acute treatment-related toxicity.]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
response rates
Time Frame: Time Frame: after 56 days (after 4 cycles - each cycle is equal to 14 days)
|
to evaluate response rates with the combination of lenalidomide and R-MPV as induction chemotherapy.
|
Time Frame: after 56 days (after 4 cycles - each cycle is equal to 14 days)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Cyclophosphamide
- Lenalidomide
- Rituximab
- Methotrexate
- Vincristine
- Busulfan
- Carmustine
- Procarbazine
Other Study ID Numbers
- "CNS-2021"
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary CNS Lymphoma
-
Matthew J. Frigault, M.D.NovartisActive, not recruitingPrimary CNS Lymphoma | Refractory Primary CNS Lymphoma | Relapsed Primary CNS LymphomaUnited States
-
Mingzhi ZhangZhengzhou UniversityUnknown
-
Mingzhi ZhangZhengzhou UniversityCompleted
-
Huiqiang HuangGuangdong 999 Brain HospitalNot yet recruitingNon Hodgkin Lymphoma | PCNSL | Refractory and Relapsed Primary CNS LymphomaChina
-
Ono Pharmaceutical Co. LtdRecruitingPrimary CNS Lymphoma | Refractory Primary Central Nervous System LymphomaUnited States
-
Charite University, Berlin, GermanyPfizerUnknownRecurrent or Refractory Primary CNS LymphomaGermany
-
Guangdong Provincial People's HospitalUnknownPrimary CNS LymphomaChina
-
Singapore General HospitalNational University Hospital, Singapore; National Cancer Center Singapore,... and other collaboratorsWithdrawnEBV Related Non-Hodgkin's Lymphoma | Primary CNS Lymphoma | Primary Testicular LymphomaSingapore
-
Rabin Medical CenterJanssen, LPRecruitingCentral Nervous System LymphomaIsrael
-
James RubensteinNational Cancer Institute (NCI)RecruitingPrimary CNS LymphomaUnited States
Clinical Trials on Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
-
Memorial Sloan Kettering Cancer CenterColumbia University; University of Vermont; University of Virginia; Northwestern... and other collaboratorsCompleted
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.; Janssen Biotech, Inc.RecruitingAdult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)United States
-
Hebei Yanda HospitalBeijing Tiantan HospitalUnknownRecurrent High-grade GliomaChina
-
European Organisation for Research and Treatment...Medical Research CouncilCompletedBrain and Central Nervous System TumorsFrance, Switzerland, Netherlands, United Kingdom, Belgium, Germany, Italy, Sweden, Finland, Portugal, Austria, Hungary
-
Assistance Publique - Hôpitaux de ParisFrench Innovative Leukemia OrganisationUnknown
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG Oncology; Eastern Cooperative Oncology Group and other collaboratorsCompletedBrain and Central Nervous System Tumors
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaboratorsCompletedBrain and Central Nervous System TumorsUnited States
-
Institute of Cancer Research, United KingdomCompletedBrain and Central Nervous System TumorsUnited Kingdom
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Canadian Cancer Trials Group; European Organisation...RecruitingBrain and Central Nervous System TumorsUnited States, Canada, France, Netherlands, Austria, Belgium
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States